Pancreas
General
World Health Organization (WHO) classification of tumors
Copyright: 2002-2020, PathologyOutlines.com, Inc.
PubMed Search: Pancreas tumor "WHO classification"
General
World Health Organization (WHO) classification of tumors
Author: Wei Chen, M.D., Ph.D.
Editorial Board Members: Andrey Bychkov, M.D., Ph.D. , Raul S. Gonzalez, M.D.
Topic Completed: 1 August 2017
Minor changes: 7 April 2020
Copyright: 2002-2020, PathologyOutlines.com, Inc.
PubMed Search: Pancreas tumor "WHO classification"
Cite this page: Chen W. World Health Organization (WHO) classification of tumors. PathologyOutlines.com website. http://www.pathologyoutlines.com/topic/pancreaswho.html. Accessed July 4th, 2020.
Definition / general
- WHO classification of tumors of the pancreas
- Currently on 4th edition, published in 2010
- Based on histologic appearance, not molecular characteristics
- Similar classification used in College of American Pathologists protocol for examination of pancreas specimens
WHO 2010 Classification
-
Epithelial tumors
- 8551/0 Acinar cell cystadenoma
- 8441/0 Serous cystadenoma
- 8148/2 Pancreatic intraepithelial neoplasia, grade 3 (PanIN-3)
- 8453/0 Intraductal papillary mucinous neoplasm (IPMN) with low or intermediate grade dysplasia
- 8453/2 Intraductal papillary mucinous neoplasm (IPMN) with high grade dysplasia
- 8503/2 Intraductal tubulopapillary neoplasm (ITPN)
- 8470/0 Mucinous cystic neoplasm (MCN) with low or intermediate grade dysplasia
- 8470/2 Mucinous cystic neoplasm (MCN) with high grade dysplasia
- 8500/3 Ductal adenocarcinoma
- 8560/3 Adenosquamous carcinoma
- 8480/3 Mucinous adenocarcinoma
- 8576/3 Hepatoid carcinoma
- 8510/3 Medullary carcinoma
- 8490/3 Signet ring cell carcinoma
- 8020/3 Undifferentiated carcinoma
- 8035/3 Undifferentiated carcinoma with osteoclast-like cells
- 8550/3 Acinar cell carcinoma
- 8551/3 Acinar cell cystadenocarcinoma
- 8453/3 Intraductal papillary mucinous neoplasm (IPMN) with an associated invasive carcinoma
- 8552/3 Mixed acinar ductal carcinoma
- 8154/3 Mixed acinar neuroendocrine carcinoma
- 8154/3 Mixed acinar neuroendocrine ductal carcinoma
- 8154/3 Mixed ductal neuroendocrine carcinoma
- 8470/3 Mucinous cystic neoplasm (MCN) with an associated invasive carcinoma
- 8971/3 Pancreatoblastoma
- 8441/3 Serous cystadenocarcinoma
- 8452/3 Solid pseudopapillary neoplasm
- Nonfunctioning (nonsyndromic) neuroendocrine tumors
- 8150/0 Pancreatic neuroendocrine microadenoma
- 8150/3 Nonfunctioning pancreatic neuroendocrine tumor
- 8151/3 Insulinoma
- 8152/3 Glucagonoma
- 8156/3 Somatostatinoma
- 8153/3 Gastrinoma
- 8155/3 VIPoma
- Serotonin producing tumors with and without carcinoid syndrome
- 8241/3 Serotonin producing tumour
- ACTH producing tumor with Cushing syndrome
- 8158/3ACTH producing tumour with Cushing syndrome
- Pancreatic neuroendocrine carcinoma (poorly differentiated neuroendocrine neoplasm)
- 8246/3 Neuroendocrine carcinoma (poorly differentiated neuroendocrine neoplasm)
- 8041/3 Small cell neuroendocrine carcinoma
- 8013/3 Large cell neuroendocrine carcinoma
- 8154/3 Mixed neuroendocrine nonneuroendocrine neoplasms
- 8154/3 Mixed ductal neuroendocrine carcinoma
- 8154/3 Mixed acinar neuroendocrine carcinoma
BenignICD 0 codes
Premalignant lesions*ICD 0 codes
Malignant lesionsICD 0 codes
Neoplasms of the neuroendocrine pancreas ICD 0 codes
Updated to the 2017 classification:
Lloyd: WHO Classification of Tumours of Endocrine Organs (IARC WHO Classification of Tumours), Fourth Edition, 2017
Mature teratoma
-
Mesenchymal tumorsICD 0 codes
- 9170/0 Lymphangioma
- 8850/0 Lipoma
- 8815/1 Solitary fibrous tumor
- Perivascular epithelioid cell neoplasm (PEComa)
- 9260/3 Ewing sarcoma
- 8806/3 Desmoplastic small round cell tumor
LymphomasICD 0 codes - 9680/3 Diffuse large B cell lymphoma (DLBCL)
- 9690/3 Follicular lymphoma
- 9699/3Lymphoma of mucosa associated lymphoid tissue (MALT lymphoma)
- T cell lymphomas
Secondary tumors
Note: * According to the Baltimore Consensus Meeting (2015), a two tiered system (low vs. high grade) is proposed for all pancreatic precursor lesions, with the provision that the current intermediate grade dysplasia now be categorized as low grade. High grade dysplasia is to be reserved for only the upper most end of the spectrum ("carcinoma in situ" type lesions).
